An Open-Label Biomarker Study of BHV-1300 in Graves' Disease
An Open-Label Biomarker Study of BHV-1300 in Graves' Disease
The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.
Key Inclusion Criteria:
1. Participants must have serologically confirmed Graves' Disease.
Key Exclusion Criteria:
clinicaltrials@biohavenpharma.com203-404-0410